^
    Back
    Association details:
    Biomarker:MTAP mutation
    Cancer:Urothelial Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).

    Published date:
    05/25/2023
    Excerpt:
    In pts with aUC receiving ICI, the presence of MTAP alt was significantly associated with lower ORR and a trend towards shorter PFS compared to absence of MTAP alt.
    DOI:
    10.1200/JCO.2023.41.16_suppl.4574